Eur Respir J 2016; 48: 808–817 | DOI: 10.1183/13993003.00840-2016
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
A Guide For Multicentre Trials in High-Burden Countries
Lancet Respir Med 2017; 5: 291–360Vol, 5 April 2017
PLOS Medicine | www.plosmedicine.org
January 2013 | Volume 10 | Issue 1 | e1001371
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...men characteristics corresponding to the needs of end-users.
more
Chen et al. BMC Public Health 2014, 14:776 http://www.biomedcentral.com/1471-2458/14/776
Male circumcision reduces a man’s risk of heterosexual acquisition of HIV by about 60%. This guideline provides an evidence-based recommendation on the use of adult male circumcision devices for HIV prevention in public health programmes in high HIV prevalence, resource-limited settings. It also p...resents key programmatic considerations for the introduction and use of these devices in public health HIV prevention programmes. The primary audiences are policy- and decision-makers, programme managers, health-care providers, donors and implementing agencies.
more
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
Public Report
PQMC 0003-003-00 WHO PQMC PR June/2015, version 2.0
4ª edição
Nos próximos meses, a COVID Reference apresentará atualizações regulares e narrará os dados científicos o mais coerente possível.
6a edición clínica. Nuevo: 4. Vacunas (26 de abril); Nuevo: 5. Pruebas y procedimientos de diagnóstico (7 de abril); Nuevo: 7. COVID-19 persistente (7 de abril)
14 July 2021 This article is part of a series of explainers on vaccine development and distribution. Learn more about vaccines – from how they work and how they’re made to ensuring safety and equitable access – in WHO’s Vaccines Explained series.
COVID-19 vaccines have proven to be safe, ...effective and life-saving. Like all vaccines, they do not fully protect everyone who is vaccinated, and we do not yet know how well they can prevent people from transmitting the virus to others. So as well as getting vaccinated, we must also continue with other measures to fight the pandemic.
Available in English, French, Spanish, Arabic, Chinese and Russian
more
BMJ Open Science 2021;5:e100202. doi:10.1136/
bmjos-2021-100202